Answers are grounded in this paper and cite their sources.
Background Deucrictibant (PHA-022121) is a novel orally bioavailable bradykinin B2 receptor antagonist under development for prophylaxis and on-demand treatment of bradykinin-mediated angioedema attacks. This study aimed to assess the pharmacological effect of deucrictibant in a bradykinin-challenge model in monkeys, to determine the pharmacologically effective concentration (EC) range in a bradykinin-challenge model in humans, and to inform dose selection for clinical trials of deucrictibant in bradykinin-mediated angioedema. Methods A bradykinin-challenge model was developed in cynomolgus monkeys and applied to healthy participants. In monkeys, effects of deucrictibant on repeated bradykinin-induced transient changes in mean arterial blood pressure (MABP) were evaluated and compared with the effects of icatibant, which was used to pharmacologically validate the model. In humans, the pharmacokinetic/pharmacodynamic (PK/PD) relationship of deucrictibant was established by assessing plasma levels and deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. Results Deucrictibant effectively inhibited bradykinin-induced changes in MABP in monkeys with a shorter time to maximal observed effect and a longer duration of effect than icatibant. In humans, single oral doses of deucrictibant (12 and 22 mg) inhibited bradykinin-induced hemodynamic changes from 1 h (first time point measured) onward. PK/PD modeling of human data estimated that plasma concentrations corresponding to the EC 50 of 2.4 ng/mL and EC 85 of 13.8 ng/mL could be maintained for at least 12 h. These parameters provided guidance for the anticipated therapeutic efficacy threshold for deucrictibant in both prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks, informing the selection of dose regimens of deucrictibant for Phase 2 clinical trials. Conclusion Bradykinin-challenge studies in monkeys and humans demonstrated deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. The results enabled selection of the Phase 2 dose regimens of deucrictibant that proved to be efficacious in prophylaxis and on-demand clinical trials in bradykinin-mediated angioedema. Clinical trial registration https://clinicaltrials.gov/study/NCT05047185 , identifier NCT05047185; RAPIDe-1: https://clinicaltrials.gov/study/NCT04618211 , identifier NCT04618211.
No takes yet. Share an insight, caveat, or question.
Lesage et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: